Post-exposure prophylaxis in leprosy (PEOPLE): a cluster randomised trial

Background Post-exposure prophylaxis (PEP) using single-dose rifampicin reduces progression from infection with Mycobacterium leprae to leprosy disease. We compared effectiveness of different administration modalities, using a higher (20 mg/kg) dose of rifampicin-single double-dose rifampicin (SDDR)-PEP. Methods We did a cluster randomised study in 16 villages in Madagascar and 48 villages in Comoros. Villages were randomly assigned to four study arms and inhabitants were screened once a year for leprosy, for 4 consecutive years. All permanent residents (no age restriction) were eligible to participate and all identified patients with leprosy were treated with multidrug therapy (SDDR-PEP was provided to asymptomatic contacts aged ≥2 years). Arm 1 was the comparator arm, in which no PEP was provided. In arm 2, SDDR-PEP was provided to household contacts of patients with leprosy, whereas arm 3 extended SDDR-PEP to anyone living within 100 m. In arm 4, SDDR-PEP was offered to household contacts and to anyone living within 100 m and testing positive to anti-phenolic glycolipid-I. The main outcome was the incidence rate ratio (IRR) of leprosy between the comparator arm and each of the intervention arms. We also assessed the individual protective effect of SDDR-PEP and explored spatial associations. This trial is registered with ClinicalTrials.gov, NCT03662022, and is completed. Findings Between Jan 11, 2019, and Jan 16, 2023, we enrolled 109 436 individuals, of whom 95 762 had evaluable followup data. Our primary analysis showed a non-significant reduction in leprosy incidence in arm 2 (IRR 0•95), arm 3 (IRR 0•80), and arm 4 (IRR 0•58). After controlling for baseline prevalence, the reduction in arm 3 became stronger and significant (IRR 0•56, p=0•0030). At an individual level SDDR-PEP was also protective with an IRR of 0•55 (p=0•0050). Risk of leprosy was two to four times higher for those living within 75 m of an index patient at baseline. Interpretation SDDR-PEP appears to protect against leprosy but less than ...